- Biolog, Inc. announced today that it has established a Joint Venture and developed a clinical microbiological identification and susceptibility system with Shanghai Fosun Medical Systems. This new system will be produced in
and is launched within the
. The system, called Bio-Fosun, is designed to improve the simplicity, speed, and accuracy of bacterial identification and targeted at mid-sized hospitals and medical laboratories worldwide. The Bio-Fosun system is easily localizable into virtually any language and is capable of being customized for different antimicrobial formularies and testing requirements. The Bio-Fosun system is being featured at Medica 2005 this week and is being launched within the PROC by Fosun Medical Technologies. For sales outside of
, Biolog retains the rights to market and sell the product.
As with all other Biolog products, the new system identifies far more bacterial species than competing systems. This is important because clinical microbiologists are finding a much wider range of microbial species causing infections because of trends like new and emerging pathogens and increasing numbers of immuno-compromised patients.
Biolog is continuing to develop its innovative OmniLog® and MicroLog microbiology identification technology and is applying it to new and exciting areas of growth. The development associated with the Joint Venture product expands Biolog’s capability and will complement applications already developed for use with bacteria, yeast, and filamentous fungi.
The clinical microbiology identification and susceptibility test market is $550 million annually, and is growing rapidly in emerging markets and steadily in developed markets. These new products represent an accurate, rapid, and cost effective alternative to existing systems already on the market. This new platform will allow clinical microbiologists to easily and efficiently process their clinical identifications and susceptibility tests.
Biolog, a privately held company based in
is a pioneer in the development of powerful new cell analysis tools for solving critical problems in clinical, pharmaceutical, and biotechnology research and development. The company’s Phenotype MicroArray technology and Microbiology Identification Systems are used in laboratories throughout the world.
Fosun is a leading private conglomerate in
. Fosun controls more than 100 subsidiary companies and provides approximately 60,000 job opportunities nationwide. The company focus is on business sectors in which they have competitive strength and growth potential. Fosun's subsidiary companies primarily operate in healthcare, real estate, steel, and retail industries.
Further information can be obtained at the companies’ websites, www.biolog.com and www.fosun.com.